235 related articles for article (PubMed ID: 17914095)
1. Cytochrome P450 3A5 is highly expressed in normal prostate cells but absent in prostate cancer.
Leskelä S; Honrado E; Montero-Conde C; Landa I; Cascón A; Letón R; Talavera P; Cózar JM; Concha A; Robledo M; Rodríguez-Antona C
Endocr Relat Cancer; 2007 Sep; 14(3):645-54. PubMed ID: 17914095
[TBL] [Abstract][Full Text] [Related]
2. CYP3A5 gene polymorphism and risk of prostate cancer in a Japanese population.
Zhenhua L; Tsuchiya N; Narita S; Inoue T; Horikawa Y; Kakinuma H; Kato T; Ogawa O; Habuchi T
Cancer Lett; 2005 Jul; 225(2):237-43. PubMed ID: 15876487
[TBL] [Abstract][Full Text] [Related]
3. Characterization of androgen-regulated expression of CYP3A5 in human prostate.
Moilanen AM; Hakkola J; Vaarala MH; Kauppila S; Hirvikoski P; Vuoristo JT; Edwards RJ; Paavonen TK
Carcinogenesis; 2007 May; 28(5):916-21. PubMed ID: 17116727
[TBL] [Abstract][Full Text] [Related]
4. Expression of paclitaxel-inactivating CYP3A activity in human colorectal cancer: implications for drug therapy.
Martínez C; García-Martín E; Pizarro RM; García-Gamito FJ; Agúndez JA
Br J Cancer; 2002 Sep; 87(6):681-6. PubMed ID: 12237780
[TBL] [Abstract][Full Text] [Related]
5. Bimodal distribution of renal cytochrome P450 3A activity in humans.
Haehner BD; Gorski JC; Vandenbranden M; Wrighton SA; Janardan SK; Watkins PB; Hall SD
Mol Pharmacol; 1996 Jul; 50(1):52-9. PubMed ID: 8700118
[TBL] [Abstract][Full Text] [Related]
6. Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein.
Yamakoshi Y; Kishimoto T; Sugimura K; Kawashima H
Biochem Biophys Res Commun; 1999 Jul; 260(3):676-81. PubMed ID: 10403825
[TBL] [Abstract][Full Text] [Related]
7. A novel transcript from the KLKP1 gene is androgen regulated, down-regulated during prostate cancer progression and encodes the first non-serine protease identified from the human kallikrein gene locus.
Kaushal A; Myers SA; Dong Y; Lai J; Tan OL; Bui LT; Hunt ML; Digby MR; Samaratunga H; Gardiner RA; Clements JA; Hooper JD
Prostate; 2008 Mar; 68(4):381-99. PubMed ID: 18196551
[TBL] [Abstract][Full Text] [Related]
8. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression.
Kuehl P; Zhang J; Lin Y; Lamba J; Assem M; Schuetz J; Watkins PB; Daly A; Wrighton SA; Hall SD; Maurel P; Relling M; Brimer C; Yasuda K; Venkataramanan R; Strom S; Thummel K; Boguski MS; Schuetz E
Nat Genet; 2001 Apr; 27(4):383-91. PubMed ID: 11279519
[TBL] [Abstract][Full Text] [Related]
9. Cytochrome P450 CYP3A in human renal cell cancer.
Murray GI; McFadyen MC; Mitchell RT; Cheung YL; Kerr AC; Melvin WT
Br J Cancer; 1999 Apr; 79(11-12):1836-42. PubMed ID: 10206301
[TBL] [Abstract][Full Text] [Related]
10. Multiplex PCR-pyrosequencing assay for genotyping CYP3A5 polymorphisms.
Aquilante CL; Langaee TY; Anderson PL; Zineh I; Fletcher CV
Clin Chim Acta; 2006 Oct; 372(1-2):195-8. PubMed ID: 16701601
[TBL] [Abstract][Full Text] [Related]
11. Unmethylated E-cadherin gene expression is significantly associated with metastatic human prostate cancer cells in bone.
Saha B; Kaur P; Tsao-Wei D; Naritoku WY; Groshen S; Datar RH; Jones LW; Imam SA
Prostate; 2008 Nov; 68(15):1681-8. PubMed ID: 18712716
[TBL] [Abstract][Full Text] [Related]
12. The role of prostate specific membrane antigen and pepsinogen C tissue expression as an adjunctive method to prostate cancer diagnosis.
Antunes AA; Leite KR; Sousa-Canavez JM; Camara-Lopes LH; Srougi M
J Urol; 2009 Feb; 181(2):594-600. PubMed ID: 19084862
[TBL] [Abstract][Full Text] [Related]
13. CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy.
Wong M; Balleine RL; Collins M; Liddle C; Clarke CL; Gurney H
Clin Pharmacol Ther; 2004 Jun; 75(6):529-38. PubMed ID: 15179407
[TBL] [Abstract][Full Text] [Related]
14. [The specific expression profile of homeobox gene NKX3.1 mRNA and protein in prostate tissues and its relationship with primary prostate cancer].
Yang GS; Wang YM; Chen ZD
Zhonghua Nan Ke Xue; 2006 Feb; 12(2):137-40, 144. PubMed ID: 16519150
[TBL] [Abstract][Full Text] [Related]
15. Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia.
Zhao Z; Liu J; Li S; Shen W
Prostate; 2009 Sep; 69(12):1292-302. PubMed ID: 19462463
[TBL] [Abstract][Full Text] [Related]
16. Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA.
Koch I; Weil R; Wolbold R; Brockmöller J; Hustert E; Burk O; Nuessler A; Neuhaus P; Eichelbaum M; Zanger U; Wojnowski L
Drug Metab Dispos; 2002 Oct; 30(10):1108-14. PubMed ID: 12228187
[TBL] [Abstract][Full Text] [Related]
17. Significance of pituitary tumor transforming gene 1 (PTTG1) in prostate cancer.
Zhu X; Mao Z; Na Y; Guo Y; Wang X; Xin D
Anticancer Res; 2006; 26(2A):1253-9. PubMed ID: 16619532
[TBL] [Abstract][Full Text] [Related]
18. Association between cytochrome P450 3A5 polymorphism and the lung function in Saskatchewan grain workers.
Seo T; Pahwa P; McDuffie HH; Yurube K; Egoshi M; Umemoto Y; Ghosh S; Fukushima Y; Nakagawa K
Pharmacogenet Genomics; 2008 Jun; 18(6):487-93. PubMed ID: 18496128
[TBL] [Abstract][Full Text] [Related]
19. Cytochrome P450 3A gene variation, steroid hormone serum levels and prostate cancer--The Rotterdam Study.
Siemes C; Visser LE; de Jong FH; Coebergh JW; Uitterlinden AG; Hofman A; Stricker BH; van Schaik RH
Steroids; 2010 Dec; 75(12):1024-32. PubMed ID: 20621111
[TBL] [Abstract][Full Text] [Related]
20. The influence of CYP3A5 expression on the extent of hepatic CYP3A inhibition is substrate-dependent: an in vitro-in vivo evaluation.
Isoherranen N; Ludington SR; Givens RC; Lamba JK; Pusek SN; Dees EC; Blough DK; Iwanaga K; Hawke RL; Schuetz EG; Watkins PB; Thummel KE; Paine MF
Drug Metab Dispos; 2008 Jan; 36(1):146-54. PubMed ID: 17954524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
